T-cell responses at the host: tumour interface
- PMID: 3539199
- DOI: 10.1016/0304-419x(86)90019-3
T-cell responses at the host: tumour interface
Abstract
The evidence considered here reinforces the conclusion that T-cell responses to tumours involve complex cellular interactions. An attempt to summarize some of these interactions is shown. This emphasizes that not only are the interactions between the effector cell populations complicated, but that the target cell surface is also subject to variation and modification as a result of the immune response. A feature that also emerges from these studies is that most cells apparently responding to or infiltrating a tumour do not necessarily participate in its destruction, and it is in this area that experimental tumour systems have particular value. This also perhaps explains the preoccupation of experimentalists with the identification of 'the' effector cell crucial to tumour rejection. However, there is heterogeneity between systems in terms of the type of rejection response induced, but a logical basis for this heterogeneity is not established. If experimental studies could define the nature of the immune response generated by a tumour in the context of the biological features of the tumour itself, this could lead to the prediction of the immunogenicity and potential for induction of a rejection response for that tumor. Clearly, experimental tumour systems do not provide an exact reflection of the situation with human tumours. However, they may provide systems that illuminate particular aspects of the human response, and give precedents to guide the interpretation of data derived from human systems. This form of assessment is still at an early stage, but developments in the experimental field should provide a framework for the development and exploitation of T-cell responses to tumours.
Similar articles
-
Identification of tumour rejection antigens recognized by T lymphocytes.Cancer Surv. 1992;13:23-37. Cancer Surv. 1992. PMID: 1423324 Review.
-
Dissection of tumour-specific antigenicity.Cancer Surv. 1985;4(1):115-34. Cancer Surv. 1985. PMID: 3879854
-
The immunogenicity of tumour cells.Immunol Cell Biol. 1987 Aug;65 ( Pt 4):271-7. doi: 10.1038/icb.1987.31. Immunol Cell Biol. 1987. PMID: 3315981 Review.
-
Multiple tumour-specific antigens expressed on a single tumour cell.Nature. 1983 Jul 14-20;304(5922):165-7. doi: 10.1038/304165a0. Nature. 1983. PMID: 6602947
-
Allogeneic IgG combined with dendritic cell stimuli induce antitumour T-cell immunity.Nature. 2015 May 7;521(7550):99-104. doi: 10.1038/nature14424. Epub 2015 Apr 29. Nature. 2015. PMID: 25924063 Free PMC article.
Cited by
-
Studies using the anti-idiotypic monoclonal antibody 105AD7 in patients with primary and advanced colorectal cancer.Ann R Coll Surg Engl. 2002 Sep;84(5):314-8. doi: 10.1308/003588402760452402. Ann R Coll Surg Engl. 2002. PMID: 12398121 Free PMC article. Review.
-
Immune profiling in human breast cancer using high-sensitivity detection and analysis techniques.JRSM Open. 2015 Sep 22;6(9):2054270415603909. doi: 10.1177/2054270415603909. eCollection 2015 Sep. JRSM Open. 2015. PMID: 26464809 Free PMC article.
-
Factors influencing antibody-mediated cytotoxicity during the immunotherapy of Rauscher-virus-induced myeloid leukemic cells.Cancer Immunol Immunother. 1989;28(2):123-30. doi: 10.1007/BF00199112. Cancer Immunol Immunother. 1989. PMID: 2783887 Free PMC article.
-
The immune system response during development and progression of carcinogen-induced rat mammary tumors: prevention of tumor growth and restoration of immune system responsiveness by thymopentin.Breast Cancer Res Treat. 1993 Sep;27(3):221-37. doi: 10.1007/BF00665692. Breast Cancer Res Treat. 1993. PMID: 8312580
-
Global gene expression profiling in interleukin-12-induced activation of CD8(+) cytotoxic T lymphocytes against mouse mammary Carcinoma.Cell Mol Immunol. 2004 Oct;1(5):357-66. Cell Mol Immunol. 2004. PMID: 16285895 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources